Neuroscientific Biopharmaceuticals Ltd. engages in researching and developing novel peptide-based pharmaceutical products. It's research and development program is focused on developing a treatment for stroke-related brain injury and dementia or Alzheimer's disease, and a diagnostic for early-stage Alzheimer's disease. The company was founded by William Harold Clough on November 14, 2002 and is headquartered in Nedlands, Australia.